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Abstract A multidrug-resistant (MDR) subline of the immuno- 
blastic B lymphoma cell line was established by sequentially se- 
It,cting in increasing concentrations of adriamycin. The adriamy- 
cin-resistant cell line (HOBI/ADR) demonstrated resistance to 
a wide spectrum of chemotherapeutic agents including MDR 
drugs (Vinca alkaloids and anthracycline), antimicrotubule drug 
(colchicine), and DNA-damaging agents (cisplatin and mitomycin 
(i). The expression of human mdrl gene, as analyzed by RT-PCR 
and Western blotting, revealed a 13-15-fold increase in resistant 
cells. Unexpectedly, HOBl lADR cells demonstrated a lack of 
reduced accumulation and of enhanced efllux of adriamycin. 
More than 60% adriamycin was effluxed at the same rate in both 
cell lines within 10 rain. In contrast, the initial rate of vincristine 
accumulation was reduced by 3 fold in this resistant cell line. The 
maximal level of vincristine accumulation was 50% lower in the 
resistant cells than the parental cells. The maximal efflux rate 
was enhanced by 5 fold in the resistant cells. Inhibition of vin- 
cristine resistance by verapamil associated with restoration of 
drug accumulation, suggesting that acquired resistance in these 
cells is due to P-glycoprotein. These studies demonstrated that 
immunohlastic B lymphoma cells selected for adriamycin re- 
sistance preferentially developed P-glycoprotein-mediated vin- 
cristine efflux which plays an important role in vincristine re- 
sistance. In contrast, the resistant cells did not elevate adriamycin 
efflux, suggesting an additional mechanism responsible for adri- 
amycin resistance. 
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1. Introduction 
Resistant cells occasionally arise from residual tumors dur- 
ing chemotherapy. Different reatment strategy in chemother- 
:~.py may affect the type of resistant umor cells. Multidrug 
esistance (MDR) appears to be a major obstacle to chemo- 
herapeutic success. Selection of numerous cell lines in vitro to 
~tudy the MDR phenomenon by a single anticancer drug, such 
ts an anthracycline, a Vinca alkaloid, or a taxane often results 
n a coordinate resistance to other structurally and functionally 
mrelated rugs [1-7]. In many instances, MDR-cells overex- 
~ress P-glycoprotein, a 150,000-180,000 Da integral membrane 
~rotein, by the mdrl gene which is believed to confer resistance 
:Corresponding author. 
Ibbreviations: DMEM, Delbecco's modified Eagle's medium; EBV, 
?,pstein-Barrvirus; MDR, multidrug resistance; MTT, 3-(4,5-dimeth- 
.'lthiazol-2-yl)-2, 5-diphenyltetrazolium bromide; PAGE, poly- 
,tcrylamide gel electrophoresis; PBS, phosphate-buffered saline; RT- 
J'CR, reverse transcription-polymerase chain reaction. 
by acting as a drug efflux pump [8 10]. Resistant sublines how 
increased efflux of cytotoxic agents and reduced intracellular 
drug accumulation [8for review; 11]. However, a number of cell 
lines have been described, such as the human small cell lung 
cancer cell line H69AR [7,12,13] and the human non-small cell 
lung cancer cell line PC-9 [14], which display multidrug resis- 
tance but do not overexpress P-glycoprotein. Recently, cDNA 
clones corresponding to an mRNA encoding a 190,000 Da 
integral membrane protein (designated multidrug resistance- 
associated protein (MRP)) markedly overexpressed in H59AR 
cells were isolated and characterized [15]. MRP belongs to the 
same superfamily of ATP-binding cassette transporter protein 
as P-glycoprotein [16,17]. Whereas, cells resistant to genotoxic 
agents uch as cisplatin are due to either one or a combination 
of the several mechanisms, including reduced rug accumula- 
tion and enhanced DNA repair independent of P-glycoprotein 
[18 for review;19]. Multidrug resistance in the clinical setting 
appears to be multifactorial nd may involve mechanisms be- 
sides P-glycoprotein overexpression [20]. A clinical case in our 
hands showed lack of response of an extranodal immunoblastic 
lymphoma to chemotherapy in a Taiwanese male patient [21]. 
The patient failed to respond to a combination of CHOP (cy- 
clophosphamide, adriamycin, vincristine and prednisone) and 
MOPP (nitrogen mustard, vincristine, procarbazine and 
prednisone) chemotherapy regimens, and died three months 
following treatment. A lymphoma cell line (termed HOB1), 
which overexpresses c-H-ras and c-myc oncogenes, was estab- 
lished from the patient [21]. In this study, an adriamycin-re- 
sistant cell line was established from HOBI cells, which showed 
MDR phenotype including P-glycoprotein-mediated drug re- 
sistance. However, the resistant lymphoma cells did not demon- 
strate an enhanced efflux and reduced accumulation of the 
selecting agent. 
2. Materials and methods 
2.1. Chemicals, drugs, and sera 
Chemotherapeutic drugs and cytotoxic agents (Adriamycin, colchi- 
cine, mitomycin C, cisplatin, puromycin, and vinblastine) were pur- 
chased from Sigma, St. Louis, MO. Dulbecco's modified Eagle's me- 
dium (DMEM), fetal bovine serum (FBS), and penicillin and strepto- 
mycin were ordered from Gibco, Gaithersburg, MD. RPMI-1640 me- 
dium was purchased from Hyclone (Logan, Utah). 
2.2. Cells and drug sensitivity 
Human lymphoma HOB1 cell line was established from a gingival 
biopsy of a male Taiwanese patient having immunoblastic lymphoma 
[21]. The cells were maintained in RPMI-1640 medium supplemented 
with 10% FBS, and 100 units/ml penicillin and 100/lg/ml streptomycin. 
The adriamycin-resistant HOB1 cell line (HOB1/ADR) was established 
from an initial exposure of HOB1 cells to a low concentration of 
adriamycin (0.001/lg/ml), followed by a 10-fold increment of the drug 
concentration up to 0.1/lg/ml. HOB1/ADR cells were cultured in this 
drug concentration to maintain resistant phenotype, and grown in 
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drug-free medium for three population doublings before experiments. 
Parental and resistant pairs of colon adenocarcinoma cells (SW620, 
SW620/MDR) and non small-cell ung cancer cells (PC9 and PC9/ 
VCR) were cultured as previously described [14,22]. Drug sensitivity 
was determined by drug-induced growth inhibition of cells using MTT 
dye (3-(4,5-dimethylthiazol)-2,5-diphenyltetrazilium bromide) (Sigma) 
method as described by Mosmann [23]. The drug resistance of the cells 
is defined as the ratio of IC50, the drug concentration causing 50% cell 
growth inhibition, of resistant cells divided by that of parental cells. 
2.3. RNA detection by RT-PCR 
DNA and RNA, and the related enzymatic reactions for reverse 
transcription and polymerase-chain reaction (RT-PCR) were prepared 
and conducted by accepted methods [24]. PCR was performed with 
cDNA transcribed from 50 ng of total RNA, 1 unit of Taq DNA 
Polymerase (Stratagene) in a microprocessor-driven thermal cycler 
(Perkin-Elmmer/Cetus) in a final volume of 25/11 reaction buffer. Each 
cycle of PCR included enaturation at95°C for 30 s, primer annealing 
at 55°C for 1 min, and extension/synthesis at 72°C for 2 min. PCR 
primers were synthesized in an Applied Biosystems DNA synthesizer 
(model 380B); the primer yield and quality were tested by UV spectros- 
copy and gel electrophoresis. Each primer was included at 37.5 pmol 
per reaction. MDRl-specific sequences were amplified by using the 
sense-strand primer 5'-GAGGTGAAGAAGGGCCAGACG-Y (nu- 
cleotides 3175-3195 relative to the first nucleotide of translation i itia- 
tion codon) and the antisense-strand primer 5'-TTCTGGATGGTG- 
GACAGGCGGTGA-3' (nucleotides 3716-3693) [25]; PCR using these 
primers yields a 542-bp product. PCR primers used for amplification 
offl2-microglobulin-specific sequences were 5'-ACCCCCACTGAAA- 
AAGATGA-Y (nucleotides 1544-1563; sense strand) and 5'-ATCTT- 
CAAACCTCCATGATG-3' (nucleotide 2253-2262 and 3507-3516; 
antisense strand) [26]; PCR using these primers yields a 114-bp roduct. 
For quantitation, 2 pCi of [~-32p]dCTP (3000 Ci/mmol; Amersham) 
was added to each reaction mixture. PCR products were separated on 
12% polyacrylamide g ls, dried and exposed to X-ray films (X-AR5, 
Kodak) in cassettes with an intensifying screen at -70°C. Films and 
intensifying screens were calibrated by different ime exposure of the 
standard [~-32p]dCTP. Autoradiographs were determined by 10 scans 
of one-dimensional densitometry (Hoefer GS300). 
2.4. Protein detection by Western blotting 
A polyclonal antibody to P-glycoprotein, mdr (Ab-1), was purchased 
from Oncogene Science, Inc., Uniodale, New York. For Western blot- 
ting, cellular proteins were separated on 10% SDS-PAGE in duplicates, 
and visualized by silver staining according to Laemmli [27] or processed 
for immunostaining with the antiserum for 3 h, treated by the avidin- 
biotin-peroxidase complex method, and stained with hematoxylin and 
photographed [28]. 
2.5. Drug accumulation study 
Drug uptake and efflux was determined by a modification of 
Lemontt et al. [29]. Exactly 10 6 cells were mixed with 0.5 ml of serum- 
free medium containing 0.5 /zM of [14C]adriamycin (55 mCi/mmol; 
Amersham) or [14C]vincristine (6.5 Ci/mmol; Amersham). For drug 
uptake analysis, labeled cells were layered onto 0.2 ml of a silicon 
oil:mineral oil mixture (5:1, v/v) and centrifuged for 10 s at 
12,000 x g. The cell pellets were washed 3-4 times with the medium. 
Radioactivity was counted in 2-ml of scintillation cocktail T (BDH 
Laboratory Supplies, England) in a Beckman LS5000TD liquid scintil- 
lation counter. For drug efflux analysis, cells were depleted of ATP with 
20 ng/ml retenone (Sigma) before being loaded with 0.5 pM of [14C]adri- 
amycin (25°C, 1 h). The cells were centrifuged, and drug efflux was 
initiated by resuspending the cell pellets in the medium and incubating 
at 25°C. At specific times 0.8 ml of the cell suspension (106 cells) were 
extracted. The aqueous medium (0.8 ml) remaining over the oil was 
removed for radioactivity counting as described above. 
3. Results 
3.1. Viability and cell growth in response to drugs 
HOB 1/ADR, an adriamycin-resistant human immunoblastic 
lymphoma cell line, was established from HOB1 [21]. Cytotox- 
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Fig. 1. Drug sensitivity and cell growth pattern in HOB1 and HOB1/ 
ADR cells. Upper Panel: % cell number elative to mock-treated cells 
was determined by MTT assay. Points, means; bars, + S.D.; n = 5. 
Lower panel: cell growth pattern was estimated for 10 days 
(means + S.D.; n = 5). 
icity, determined by MTT (Fig. 1, upper panel) exhibited a 
240-fold resistance to the selecting drug. The dose-response in
the resistant cells demonstrated a 'shoulder' at low concentra- 
tions of ADR (within 1/tg/ml)). In contrast, the parental cells 
lacked a tolerance response. The IC50 was 0.05 and 12 for 
parental and resistant cells, respectively. Cell growth curve was 
also measured (Fig. 1, lower panel). Both cell lines exhibited a
similar population doubling time, 22-24 h. Resistance of 
HOB 1/ADR cells to other cytotoxic agents was also estimated. 
Calculated IC50 values are listed in Table 1. HOB1/ADR cells 
also demonstrated high resistance to MDR-type drugs: colchi- 
cine (133 fold), vinblastine (500 fold), vincristine (200 fold); and 
to DNA-damaging agents: cisplatin (65 fold), mitomycin C (25 
fold). HOB1/ADR cells appeared to be resistant to a wide 
spectrum of anticancer drugs and cytotoxic agents. 
3.2. Overexpression of mdrl  gene 
The mature RNA of mdrl gene in HOB1 and HOBI /ADR 
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ceils was measured by RT-PCR (Fig, 2). Quantitation of mdrl 
amplification (HOBI/ADR vs. HOB1) was shown (Fig. 2A). 
PCR was conducted in 30 cycles using eDNA transcribed from 
1- or 10-fold diluted total RNA. The quantitated data indicated 
8 10-fold amplification of mdrl gene; or 13-15-fold amplifica- 
tion of mdrl if normalized to fl2-microblobulin. RT-PCR for 
tl~e detection of mdrl yielded a single PCR product of the 
e~pected size of 543-bp (indicated with an arrowhead in Fig. 
213). The specificity of the amplified mdrl cDNA was confirmed 
b :  partial sequence, and by the same size of PCR product 
a nplified from 50 ng of pGEM3Zf(-)-mdrl,  as plasmid DNA 
o ~ntaining full-length mdrl eDNA (a kind gift from Professor 
Pet  Borst, The Netherlands Cancer Institute). PCR product of 
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:ig. 2. (A) The fold amplification of mdr gene detected by RT-PCR. 
"he mRNA was 1- or 10-fold diluted for RT-PCR. mdrl was compared 
' .:ithout normalization or by normalizing to fl2-microtubuline. Points, 
Hleans; bars, + S.D.; n = 3. A representative example of RT-PCR was 
• hown (B). Reverse transcribed eDNA from HOBI/ADR (lanes 1 and 
) or HOB1 (lanes 2 and 4) mRNA was amplified in PCR programmed 
~a 30 reaction cycles, pGEM3Zf(-)-mdrl (lane 5) and buffer (lane 6) 
were used as controls. PCR products for mdrl andfl2-microglubulin are 
~ndicated with arrowhead and star, respectively. (C) Immunodetection 
~f P-glycoprotein. Fifty/~g of cell lysates was separated on 10% SDS- 
PAGE, and silver stained (lanes 1 and 2) or Western blotting using 
mdrl antibody (lanes 3 and 4). Lanes: 1 and 3, HOB1; lanes 2 and 4, 
ttOBI/ADR. Molecular weight size markers (in kDa) are indicated. 
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Fig. 3, Time course of the uptake and efftux of adriamycin i  HOB1 
and HOBI/ADR cells. Upper panel: Cells were incubated in medium 
containing [~4C]adriamycin for 120 rain. Lower panel: Cells were loaded 
with [~4C]adriamycin for 60 min before assay for efflux. Points, means; 
bars, + S.D.; n = 3. 
the expected size of 120 bp for fl2-microblobulin was indicated 
with a star. 
Since HOBI /ADR cells developed cross-resistance to classi- 
cal MDR drugs and overexpressed mdrl mRNA, it is reasona- 
ble to speculate that the resistance cells may overexpress P- 
glycoprotein. To test this hypothesis, 100 ~tg of cell membrane 
proteins was separated in acrylamide gel in duplicates, and 
either silver stained or processed for immunostaining with a 
commercial antibody against P-glycoprotein (Fig. 2C). Im- 
munostaining indicates that HOBI /ADR cells (lane 4) showed 
a protein band with size similar to P-glycoprotein (indicated 
with arrowheads). In contrast, HOB1 showed barely detecta- 
ble, if any, P-glycoprotein. 
3.3. Reduced accumulation of vincristine, but not adriamycin 
To analyze adriamycin accumulation, radioactive ~4C-la- 
belled adriamycin was used to study drug uptake and efflux in 
parental and resistant HOB1 cells (Fig. 3). Unexpectedly, both 
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Fig. 4. Time course of the uptake and efflux of vincristine in HOB1 and 
HOBI/ADR cells. Upper panel: Cells were incubated in medium con- 
taining [14C]vincristine for 120 min. Lower panel: Cells were loaded 
with [l~C]vincristine for 60 min before assay for efltux. Points, means; 
bars, _+ S.D.; n = 3. 
cells showed a similar accumulation rate (upper panel) and 
efflux rate (lower panel). There was a rapid uptake rate of 
adriamycin with 0.3 pmol/mg proteirdmin within 40 min, fol- 
lowed by an uptake plateau. For drug efflux, more than 60% 
of adriamycin was excluded in 10 min in both cell lines. Similar 
analysis was conducted for vincristine accumulation (Fig. 4). 
For drug uptake (upper panel), parental cells showed a nearly 
linear pattern of drug accumulation following 20 rain incuba- 
tion. There was a uptake plateau after 60 min incubation in 
HOB 1/ADR cells. For this condition, the drug uptake rate was 
about 0.075 and 0.025 pmol/mg protein/min in HOB1 and 
HOB1/ADR cells, respectively. The results indicate that the 
drug-uptake rate in HOB1/ADR cells is 3 fold lower than pa- 
rental cells. Furthermore, the resistant cells accumulated less 
vincristine than parental cells following prolonged incubation. 
Vincristine efflux was also compared in HOB1/ADR and pa- 
rental cells (Fig. 4, lower panel). Cells were incubated with 
vincristine for 60 min before the level of drug remaining in- 
tracellularly was measured. As shown, there was a rapid de- 
crease of vincristine in HOB 1/ADR cells. The rate of vincristine 
efflux was 10%/min and 0.2%/rain for HOB1 and HOB1/ADR 
cells, respectively. The drug efflux rate in HOB1/ADR cells was 
5-fold increased. Only ~50% of the drug remaining following 
50 min incubation of the resistant cells. In contrast, 90% or 
more was retained in the parental cells. Taken together, HOB1/ 
ADR cells exhibited a reduced accumulation of vincristine. 
However, adriamycin accumulation was not lowered in the 
resistant cells. 
3.4. Enhancement ofdrug accumulation by verapami! 
To test whether drug accumulation is mediated by P- 
glycoprotein, inhibition by verapamil was used. Adriamycin 
accumulation was compared in HOB1 and HOB1/ADR cells 
(Fig. 5 upper panel). As shown, there is no significant enhanc- 
ing effect by verapamil on adriamycin accumulation i  HOB 1 
and HOB1/ADR cells. Reduced adriamycin in SW620/MDR 
cells was reversed by verapamil to a level comparable to that 
in SW620 cells. Vincristine accumulation was also compared in 
the parental and resistant cells (lower panel). Cells were incu- 
bated with labelled vincristine for 60 min, and the intracellular 
level of vincristine was measured. There was 3.5 pmol/mg of 
protein in HOB1 cells, and no significant verapamil effect was 
detected. In contrast, in the presence of verapamil the vin- 
cristine level of HOB1/ADR cells increased from 2.5 to 4.2 
pmol/mg of protein, a level comparable to that in the HOB1 
cells. For comparison, SW620/MDR and SW620 cells were also 
Table 1 
Sensitivity to anticancer and cytotoxic agents of HOB1 and HOB1/ 
ADR cells 
Agents IC5o (pg/mly 
HOB1 HOBI/ADR Fold resistance b 
Adriamycin 0.05 + 0.003 12 + 0.5 240 
Colchicine 0.009 + 0.001 1.2 + 0.2 133 
Vinblastine 0.001 + 0.0003 0.5 + 0.1 500 
Vincristine 0.05 + 0.004 10 + 1.5 200 
Cisplatin 0.1 + 0.01 6 + 2 65 
Mitomycin C 0.04 + 0.005 1 + 0.08 25 
IC50 is the drug concentration effective in inhibiting 50% of the cell 
growth measured by MTT assay after 4 days of continuous exposure 
to the drug. Mean + S.D. (n = 5). 
b Fold resistance was determined by the ratio of IC50 of HOB1/ADR 
to the IC50 of HOB1 cells. 
Table 2 
Effect of verapamil on the ICs0 values of adriamycin 
Cell lines IC50 ~g/ml) a
- verapamil + verapamil Fold reduction b 
HOB1 0.05 + 0.003 0.04 + 0.004 1.25 
HOBI/ADR 11.5 + 0.5 (230) c 0.23 _+ 0.01 50 
SW620 0.53 + 0.04 0.48 + 0.05 1.1 
SW620/MDR 48 -+ 2.5 (90.6) c 0.45 _+ 0.02 106 
PC9 0.04 + 0.002 0.038 + 0.001 1.05 
PC9/VCR 0.039 + 0.007 0.037 _+ 0.005 1.05 
(0.98) c
IC50 is the drug concentration effective in inhibiting 50% of the cell 
growth measured by MTT assay after 4 days of continuous exposure 
to the drug; results are means _+ S.D. (n = 5). 
b Fold reduction was determined by the ratio of IC50 without verapamil 
divided by IC50 with verapamil (1/xg/ml). 
c Fold resistance relative to the parental cells. 
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analyzed in parallel. Verapamil restored vincristine accumula- 
ton  in SW620/MDR cells to ~30 pmol/mg of protein which is 
similar to the level in parental cells; whereas with little vera- 
I amil effect on SW620 cells. The results indicate that verapamil 
enhances the accumulation of vincristine, but not adriamycin, 
i l  HOB1/ADR cells. 
. .5. Inhibition o f  drug resistance by verapamil 
The acquired adriamycin resistance of HOB I/ADR cells was 
~zsted by a sublethal concentration of verapamil (1 pg/ml) 
Fable 2). Resistance phenotypes of P-glycoprotein-dependent 
I SW620/MDR) and independent (PC-9/VCR) cells were used 
t,s controls. ICs0 of these resistant cell lines with or without 
, erapamil is indicated in comparison with their parental coun- 
l erpart. Adriamycin resistance in HOBI/ADR cells (230 fold) 
was partially reversed by verapamil. There was 50-fold reduc- 
lion. The adriamycin resistance of SW620 and SW620/MDR 
ells was reduced by verapamil by 1.25 and 50 fold, respectively. 
n contrast, vincfistine resistance in PC-9 and PC-9/VCR cells 
'vas not affected by verapamil. The results indicate that vera- 
!~amil affects vincristine toxicity in P-glycoprotein-overex- 
~ressing SW620/MDR cells [22], but not in P-glycoprotein- 
ndependent PC-9/VCR cells [14]. Thus, adriamycin resistance 
a HOBI/ADR cells is at least partly due to P-glycoprotein. 
4. Discussion 
In this report, an MDR lymphoma cell line was selected by 
adriamycin. The resistant ceils demonstrated the overexpres- 
sion of mdrl gene, and were phenotypically sensitive to vera- 
pamil, an effective reversing agent of P-glycoprotein-mediated 
MDR [30,31]. The HOB1/ADR cells selectively pumped vin- 
cristine, but not adriamycin, out of cells, associated with cross- 
resistance to vincristine. Treatment of the HOBI/ADR cells 
with verapamil partially reversed acquired resistance, suggest- 
ing that P-glycoprotein is partly responsible for adriamycin 
resistance. A simple explanation is that a verapamil-sensitive 
mechanism(s) other than adriamycin efflux is responsible for 
the resistant phenotype in the immunoblastic lymphoma cells. 
The above observation is not due to analytical artifacts because 
verapamil clearly reverses resistance in P-glycoprotein-depend- 
ent SW620/MDR [22] but ineffective in a P-glycoprotein-inde- 
pendent resistant PC9/VCR [14]. It has previously been demon- 
strated that mutations in the P-glycoprotein gene, mdrl ,  in 
some cases, but not in others, may explain drug specificity 
[10,32]. The co-enhancement i  efflux of adriamycin and vin- 
cristine, associated with co-resistance to both drugs, was de- 
tected in SW620/MDR cells [this study;22]. Perhaps, the suble- 
thal pressure by vincristine-based chemotherapy of the patient 
[21] pre-selects for cells with potential in P-glycoprotein overex- 
pression and preferential efflux of vincristine. Further treat- 
ment of the cultured HOB1 cells with adriamycin or perhaps 
other agents establishes cells with mdrl overexpression and 
selected rug efflux. It should be interesting to have more 
detailed analysis in view of drug efflux specificity in resistant 
immunoblastic lymphoma cells. Western and Northern blotting 
analyses indicated that MRP and GST are not involved in the 
non-efflux resistance of HOB1/ADR cells (Chao, C.C.-K., un- 
published ata). Alternatively or additionally, ras overexpres- 
sion may play a role in the drug resistance of HOB1/ADR cells. 
Conflicting results have been reported that ras overexpression 
is associated with resistant phenotype in some cells [33-35] but 
not in others [36-38]. Therefore, events associated with the 
presence of an acitvated ras oncogene, such as protein kinase 
C [39,40], glutathione S-transferase [41,42], and transcriptional 
factor AP-1 [43] activities, may be related to the mechanisms 
involved in the response of HOB 1/ADR cells to adriamycin and 
other drugs. We and others have previously demonstrated that 
adriamycin-selected MDR cells are associated with overexpres- 
sion of anionic glutathione S-transferase and cytochrome P450- 
related enzymes, potentially able to inactivate anthracyclines 
and possibly other MDR drugs [22,44,45]. Perhaps, endogene- 
ously activated ras expression in parental HOB1 cells [20] in 
cooperation with other mechanism(s) elicited by the selecting 
agent results in the resistant phenotype, which is not necessary 
to be associated with drug accumulation. This is the first evi- 
dence, to my knowledge, showing adriamycin-resistant cells 
which display enhanced efflux of the other but not the selecting 
drug. 
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